Take a closer look.
When a pharmaceutical product franchise was faced with regulatory pricing pressure, new competitors, and the entry of biosimilars, they came to CRA. We analyzed their options, developed a country segmentation strategy, and recommended an optimal reaction to biosimilar entry scenarios.